Entonox (Nitrous Oxide 50% / Oxygen 50%)
Brand names: Entonox, Equanox
A ready-mixed inhaled gas of equal parts nitrous oxide and oxygen used as a rapid-onset, short-acting analgesic for procedures such as dressing changes and debridement in burns and plastics.
Adult dose
Dose adjustments
No renal dose adjustment is printed in SPC sections 4.2-4.4.
No hepatic dose adjustment is printed in SPC sections 4.2-4.4.
Dose independently re-sourced from UK Summary of Product Characteristics (SPC) via MHRA Products — clinician-reviewed. Always confirm against the product SmPC and your local formulary before prescribing.
Contraindications
- Any condition where gas is entrapped within a body and where its expansion might be dangerous, such as: artificial, traumatic or spontaneous pneumothorax; air embolism; decompression sickness; following a recent dive; following air encephalography; severe bullous emphysema; use during myringoplasty; gross abdominal distension
- Patients having received a recent intraocular injection of gas (such as SF6)
Side effects
- Commonly described: euphoria, disorientation, sedation, nausea, vomiting, dizziness and generalised tingling - generally minor and rapidly reversible
- Listed in the SPC adverse-reaction table: euphoria, dizziness, light-headedness, somnolence, nausea, vomiting, sense of intoxication, feeling of pressure in the middle ear, bloating / increased gas volume in the intestines (the table's frequency columns are not legible in the extracted text, so no frequencies are given)
- Respiratory depression, generalised seizures, confusion and addiction (also listed in the SPC adverse-reaction table, frequencies not legible in the extracted text)
- Prolonged or frequent use (including heavy occupational exposure and addiction): megaloblastic anaemia, agranulocytosis after prolonged administration, myeloneuropathy and subacute combined degeneration of the spinal cord
- Neurological toxicity after a single exposure for anaesthesia in patients with undiagnosed subclinical vitamin B12 deficiency
- Nitrous oxide passes into gas-containing body spaces faster than nitrogen passes out: prolonged exposure may result in bowel distension, middle ear damage and rupture of ear drums
Interactions
- Vitamin B12: the nitrous oxide constituent inactivates vitamin B12
- Methotrexate: the nitrous oxide constituent potentiates its effects on folate metabolism
- Bleomycin, amiodarone and nitrofurantoin or similar antibiotics: higher levels of oxygen can increase the risk of pulmonary toxicity; give Entonox with caution and at levels kept as low as possible
- Centrally acting depressants (opiates, benzodiazepines and other psychotropics): additive effects with a risk of pronounced sedation and depression of protective reflexes; use under the supervision of appropriately trained personnel
Monitoring
- Do not use for more than a total of 24 hours, or more frequently than every 4 days, without close clinical supervision and haematological monitoring; seek specialist advice from a haematologist in such cases
- Haematological assessment should include megaloblastic change in red cells and hypersegmentation of neutrophils; neurological toxicity can occur without anaemia or macrocytosis and with B12 levels in the normal range
- Caution in patients with known COPD or other conditions with compromised chemoreceptor sensitivity/function (respiratory depression and a rise in PaCO2 possible)
- Caution in patients with a known history of substance abuse (repeated administration may lead to addiction)
- Scavenge waste gas to keep ambient nitrous oxide below 100 ppm in theatre and equivalent treatment rooms
Clinical monograph
How it works
Inhaled nitrous oxide produces analgesia and light sedation through central effects including modulation of opioid and NMDA-receptor pathways, while the oxygen component maintains oxygenation.
Prescribing in practice
- It is contraindicated where gas can expand in trapped spaces, including pneumothorax, bowel obstruction and recent intraocular or middle-ear surgery and decompression illness.
- Prolonged or repeated exposure can inactivate vitamin B12 and impair folate metabolism, causing neurological and haematological harm, so cumulative use should be limited.
- Adequate room scavenging and ventilation are needed to protect staff from chronic exposure.
Monitoring
Monitor conscious level and adequacy of analgesia during use; the short half-life means recovery is rapid once inhalation stops.
Counselling the patient
- Breathe the gas through the mouthpiece during the painful part of the procedure.
- It works quickly and wears off within minutes of stopping.
- Tell staff if you feel very lightheaded, sick or unwell.
Evidence & guidelines
Entonox is a long-established inhaled analgesic for short painful procedures, with MHRA cautions regarding gas-filled spaces and vitamin B12 effects from repeated exposure.
Reference: AAGBI/Faculty of Pain Medicine Entonox Guidelines; BBA Burns Dressing Change Analgesia Protocol; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Morphine Milligram Equivalents (MME) Calculator · Pain / Opioids
- Opioid Conversion / Equianalgesic Guide · Pain Management
- Numeric Rating Scale (NRS) for Pain · Pain Assessment
- Critical-Care Pain Observation Tool (CPOT) · Pain Assessment
- Behavioral Pain Scale (BPS) for Ventilated Patients · Pain Assessment
- Rate-Pressure Product (RPP) · Haemodynamics